PCSK9 and familial hypercholesterolemia: Recently, a network meta-analysis performed by Zhao et al. reported that pharmacological treatments with statins and PCSK9 inhibitors offered a nearly identical decrease in cardiovascular events in patients with hypercholesterolemia, but PCSK9 inhibitors were the most effective agent in improving lipid levels and not associated with any increased risk of statin-related side-effects [101].